Cite
HARVARD Citation
Zeidan, A. et al. (n.d.). A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMAS) Failure. Leukemia research. pp. S43-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zeidan, A. et al. (n.d.). A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMAS) Failure. Leukemia research. pp. S43-. [Online].